Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
16 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
OBERÖSTERREICH
LINZ
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation - AT
Ordensklinikum Linz GmbH Barmherzige Schwestern
Interne I - Internistische Onkologie, Hämatologie u. Gastroenterologie
DANIMARCA
Jylland
AARHUS
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (Phase III)
Aarhus Universitetshospital - Skejby
Department of Pediatrics
FRANCIA
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 3 (ALFA0701) : A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCIA
ILE-DE-FRANCE
LE CHESNAY
MYLOfrance 4 (ALFA1401) : Gemtuzumab Ozogamicin + Cytarabine vs Idarubicin + Cytarabine in Elderly Patients With AML (Phase II-III)
CH de Versailles - Hôpital André Mignot
Service d'Hématologie - Oncologie
FRANCIA
PAYS DE LA LOIRE
NANTES
Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
GERMANIA
Baden-Württemberg
HEIDELBERG
AMLSG 09-09: Phase III Study of Chemotherapy in combination with ATRA with or without Gemtuzumab Ozogamicin in patients with Acute Myeloid Leukemia (AML) and NPM1 gene mutation - DE
Nationales Centrum für Tumorerkrankungen (NCT)
Nationales Centrum für Tumorerkrankungen (CCC) Heidelberg
GERMANIA
Sachsen
DRESDEN
Gentuzumab ozogamicin before allogeneic stem cell transplantation in patients with relapsed CD33+ Acute Myeloid Leukemia (Phase I-II) - DE
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Medizinische Klinik und Poliklinik I - Fachbereich Hämatologie und Blutstammzelltransplantation
ITALIA
FRIULI VENEZIA GIULIA
UDINE
Terapia in pazienti al di sotto dei 66 anni con Leucemia Mieloide Acuta
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Clinica Ematologica
PAESI BASSI
Gelderland
NIJMEGEN
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
PAESI BASSI
Gelderland
NIJMEGEN
Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
PAESI BASSI
Gelderland
NIJMEGEN
Idarubicin and Cytarabine in combination with Gemtuzumab Ozogamicin (IAGO) for young untreated patients without HLA identical familial donor with high risk developing MDS/AML after 6 months of the diagnosis MDS
Radboudumc - Radboud universitair medisch centrum
Afdeling Hematologie
PAESI BASSI
Gelderland
NIJMEGEN
High dose Ara-C in combination with Gemtuzumab Ozogamicin (ARGO) as salvage treatment for primary resistant AML patients 18 - 60 yrs old
Radboudumc - Radboud universitair medisch centrum
Afdeling Tumor Immunologie
REGNO UNITO; GRAN BRETAGNA
Glasgow
GLASGOW
MyeChild 01: International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy - UK
Royal Hospital For Children, NHS Greater Glasgow & Clyde
Paediatrics (Ground Floor, Zone 1)
SPAGNA
Cataluña
BARCELONA
Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity (Phase II) - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
SPAGNA
Comunidad Valenciana
VALENCIA
PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) (Phase IV) (completed)
Hospital Universitario y Politécnico La Fe
Servicio de Hematología y Hemoterapia
STATI UNITI
Connecticut
NEW HAVEN